First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study

NCT06616259 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

452

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Cancer (CRC)
Capecitabine
Cetuximab

Interventions

DRUG: mCapOX plus Cetuximab
DRUG: mFOLFOX6 plus Cetuximab

Sponsor

Meng Qiu